Sign up for free insights newsletter
B1

Boston Scientific Corporation

B1SX34SA

Need professional-grade analysis? Visit stockanalysis.com

R$359.40
-2.61%
End of day
Market Cap

$547.63B

P/E Ratio

295.38

Employees

53,000

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-3.04-2.73-2.01-1.80-1.62-1.99
Calmar-23.01-6.03-2.40-1.47-0.95-3.52
Sharpe-3.41-2.15-1.91-1.58-1.34-1.77
Omega0.120.600.420.630.730.58
Martin-40.44-9.70-3.68-3.08-2.41-6.35
Ulcer2.145.8121.6217.2416.0815.20

Boston Scientific Corporation (B1SX34) Price Performance

Boston Scientific Corporation (B1SX34) trades on SA in BRL. The company is classified in the Healthcare sector under the Medical Devices industry. The stock currently trades at BRL359.40, down 2.61% from the previous close.

Over the past year, B1SX34 has traded between a low of BRL356.87 and a high of BRL603.57. The stock has lost 38.7% over this period. It is currently 40.5% below its 52-week high.

Boston Scientific Corporation has a market capitalization of $547.63B, with a price-to-earnings ratio of 295.38.

About Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Company Info

Exchange
SA
Currency
BRL
Country
Brazil

Financial Metrics

Revenue (TTM)
$20.07B
EBITDA
$5.34B
Profit Margin
14.44%
EPS (TTM)
10.15
Book Value
85.35

Technical Indicators

52 Week High
R$604.59
52 Week Low
R$354.50
50 Day MA
R$423.22
200 Day MA
R$517.32
Beta
0.70

Valuation

Trailing P/E
36.36
Forward P/E
N/A
Price/Sales
27.28
Price/Book
4.32
Enterprise Value
$557.87B